J. Ge

发表

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

R. Greil, K. Harrington, I. Braña, 2022, Journal of Clinical Oncology.

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.

V. Grégoire, J. Machiels, K. Harrington, 2020, Future oncology.

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

M. Socinski, A. Patnaik, S. Gadgeel, 2015 .

Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

L. Sequist, H. Borghaei, A. Patnaik, 2015 .

Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant

K. Connor, D. Michelson, C. Assaid, 2017, The Clinical journal of pain.

Reply to "Keynote 48: Is it really for everyone?"

B. Burtness, J. Ge, 2020, Oral oncology.

KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma.

G. Daniels, R. Swaby, E. Cohen, 2019, Journal of Clinical Oncology.

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

R. Lipton, D. Dodick, S. Aurora, 2016, Cephalalgia : an international journal of headache.

Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.

D. Siegel, J. Miguel, N. Munshi, 2016 .

KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.

N. Lee, W. Westra, I. Braña, 2019, Journal of Clinical Oncology.

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

L. Sequist, H. Borghaei, A. Patnaik, 2016 .

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Head and Neck Squamous Cell Carcinoma

K. Emancipator, M. Jansson, K. Kulangara, 2021 .

Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2016 .

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

K. Harrington, D. Pfister, D. Rischin, 2018 .

KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC).

V. Grégoire, J. Machiels, J. Waldron, 2018, Annals of Oncology.

First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.

L. Sequist, H. Borghaei, S. Jalal, 2017 .

Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

R. Greil, K. Harrington, A. Psyrri, 2020, Bioinformatics, Convergence Science, and Systems Biology.

858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)

C. Ho, R. Swaby, N. Ngamphaiboon, 2021, Annals of Oncology.

Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy

J. Machiels, Q. Le, D. Rischin, 2022, International Journal of Radiation Oncology*Biology*Physics.